[Oral combination chemotherapy of 5'-deoxy-5-fluorouridine (furtulon) and cyclophosphamide for advanced breast cancer].
To evaluate the efficacy and safety of the oral combination chemotherapy of furtulon (FTL) and cyclophosphamide (CTX) for advanced breast cancer (ABC). From Jun 2000 to Jun 2002, eighty-three patients with ABC were treated with the two oral drugs as combined chemotherapy. The mean number of cycles was 5, median number of cycles was 6 (range 2-6). The overall response rate was 45.8%, The median time to progression was 6 months. The treatment was well tolerated, with related Grade 3 clinical adverse effect being only nausea and vomiting in 2 patients (2.4%) and mild hematologic toxicities. Oral combined chemotherapy of FTL and CTX, being convenient and safe, is effective for patients with advanced breast cancer.